Overview

This trial is active, not recruiting.

Condition parkinson's disease
Treatment far infrared radiation (5μm to 20μm wavelength)
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date May 2008
End date May 2010
Trial size 10 participants
Trial identifier NCT00674895, GAAD-PD-CTP1

Summary

Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
far infrared radiation (5μm to 20μm wavelength) Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Primary Outcomes

Measure
Cure for PD
time frame: 2 years

Secondary Outcomes

Measure
Rehabilitation of PD Patients
time frame: 2 Years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - People with Parkinson's Disease Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control and Treatment of Parkinson's Disease.
Principal investigator Ken Nedd, M.D.
Description Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. PD is both chronic and progressive. Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have PD.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..